Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.

Brewer GJ, Merajver SD.

Integr Cancer Ther. 2002 Dec;1(4):327-37. Review.

PMID:
14664727
[PubMed - indexed for MEDLINE]
2.

Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.

Brewer GJ.

Exp Biol Med (Maywood). 2001 Jul;226(7):665-73. Review.

PMID:
11444102
[PubMed - indexed for MEDLINE]
3.

Control of copper status for cancer therapy.

Goodman VL, Brewer GJ, Merajver SD.

Curr Cancer Drug Targets. 2005 Nov;5(7):543-9. Review.

PMID:
16305350
[PubMed - indexed for MEDLINE]
4.

Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.

Brewer GJ.

J Cell Mol Med. 2003 Jan-Mar;7(1):11-20. Review. Erratum in: J Cell Mol Med. 2003 Apr-Jun;7(2):1 p proceeding table of contents.

PMID:
12767257
[PubMed - indexed for MEDLINE]
5.

Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.

Brewer GJ.

Curr Cancer Drug Targets. 2005 May;5(3):195-202. Review.

PMID:
15892619
[PubMed - indexed for MEDLINE]
6.

Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.

Khan G, Merajver S.

Expert Opin Investig Drugs. 2009 Apr;18(4):541-8. doi: 10.1517/13543780902845622 . Review.

PMID:
19335282
[PubMed - indexed for MEDLINE]
7.

Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.

Brewer GJ.

Metallomics. 2009;1(3):199-206. doi: 10.1039/b901614g. Epub 2009 Apr 16. Review.

PMID:
21305118
[PubMed - indexed for MEDLINE]
8.

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD.

Clin Cancer Res. 2000 Jan;6(1):1-10.

PMID:
10656425
[PubMed - indexed for MEDLINE]
Free Article
9.

Copper deficiency as an anti-cancer strategy.

Goodman VL, Brewer GJ, Merajver SD.

Endocr Relat Cancer. 2004 Jun;11(2):255-63. Review.

PMID:
15163301
[PubMed - indexed for MEDLINE]
Free Article
10.

Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.

Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD.

Clin Cancer Res. 2003 May;9(5):1666-72.

PMID:
12738719
[PubMed - indexed for MEDLINE]
Free Article
11.

Anticopper therapy against cancer and diseases of inflammation and fibrosis.

Brewer GJ.

Drug Discov Today. 2005 Aug 15;10(16):1103-9. Review.

PMID:
16182195
[PubMed - indexed for MEDLINE]
12.

Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.

Brewer GJ, Dick R, Ullenbruch MR, Jin H, Phan SH.

J Inorg Biochem. 2004 Dec;98(12):2160-7.

PMID:
15541506
[PubMed - indexed for MEDLINE]
13.

The use of copper-lowering therapy with tetrathiomolybdate in medicine.

Brewer GJ.

Expert Opin Investig Drugs. 2009 Jan;18(1):89-97. doi: 10.1517/13543780802621859 . Review.

PMID:
19053885
[PubMed - indexed for MEDLINE]
14.

Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.

Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, Smith DC.

Oncology. 2006;71(3-4):168-75. Epub 2007 Jul 18.

PMID:
17641535
[PubMed - indexed for MEDLINE]
15.

The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.

Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD.

Laryngoscope. 2001 Apr;111(4 Pt 1):696-701.

PMID:
11359142
[PubMed - indexed for MEDLINE]
16.

Antiangiogenic therapy through copper chelation.

Sproull M, Brechbiel M, Camphausen K.

Expert Opin Ther Targets. 2003 Jun;7(3):405-9. Review.

PMID:
12783576
[PubMed - indexed for MEDLINE]
17.

Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.

Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH.

J Lab Clin Med. 2003 Mar;141(3):210-6.

PMID:
12624602
[PubMed - indexed for MEDLINE]
18.

Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.

Hou G, Dick R, Zeng C, Brewer GJ.

Transl Res. 2006 Dec;148(6):309-14.

PMID:
17162252
[PubMed - indexed for MEDLINE]
19.

Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma.

Khan MK, Mamou F, Schipper MJ, May KS, Kwitny A, Warnat A, Bolton B, Nair BM, Kariapper MS, Miller M, Brewer G, Normolle D, Merajver SD, Teknos TN.

Arch Otolaryngol Head Neck Surg. 2006 Mar;132(3):333-8.

PMID:
16549755
[PubMed - indexed for MEDLINE]
20.

Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.

Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT.

Transl Res. 2009 Aug;154(2):70-7. doi: 10.1016/j.trsl.2009.05.002. Epub 2009 Jun 6.

PMID:
19595438
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk